News
Thursday, 10 December 2020

Press Release Full Year Results

10 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its full year audited results for the year ended 31 July 2020.

C4XD's Clive Dix steps up as Interim Chair of UK Vaccine Taskforce

8 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, confirms that Clive Dix, Chief Executive Officer of C4XD has stepped into the role of Interim Chair of the UK Vaccine Taskforce, the group set up by the Government to lead UK efforts to find and manufacture a COVID-19 vaccine. The Government will set out arrangements for the long-term leadership of the Vaccine Taskforce shortly.

9 November 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce that at the General Meeting held earlier today in connection with the Company’s Placing at an Issue Price of 14.0 pence, details of which were announced on 21 October 2020, each of the Resolutions were duly passed.

Wednesday, 21 October 2020

Press Release Result of Placing

Result of Placing

and Notice of General Meeting

Successfully raises approximately £15.0 million 

Advancing the next wave of out-licensing opportunities

21 October 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce the completion of the Placing announced earlier today.

Advancing the next wave of out-licensing opportunities

21 October 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces a proposed conditional placing to raise approximately £15.0 million.

CEO Clive Dix spoke to Proactive Investors on today’s business update.

Talking about the collaboration with the GEN-COVID Consortium in Italy, Clive said "The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis."

Tuesday, 25 August 2020

Press Release Business Update

Continued progress across proprietary portfolio

Phase 1 clinical trial with C4X_3256 initiated by partner Indivior

New Taxonomy3® collaboration with the GEN-COVID Consortium, Italy, to examine COVID-19 genetics

25 August 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a business update.